TNFSF10 and lung carcinoma: Due to the homing properties of MSCs towards the tumor site, recent studies have focused on utilizing MSCs as carriers for anti-cancer agents, including MSC expressing IL-18, TRAIL, oncolytic adenovirus (CRAd5/F11), and paclitaxel-encapsulated nanoparticles in the treatment of breast cancer cells [52], B-cell acute lymphocytic leukemia [53], colorectal cancer [54], and lung cancer [55] respectively.